Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $40.00 Average Target Price From Analysts
Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $40.00 Average Target Price From Analysts
Shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) have been assigned an average recommendation of "Hold" from the seven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $40.00.
Marketbeat报告称，目前报道该股的七家经纪商已将Verve Therapeutics, Inc.（纳斯达克股票代码：VERV — Get Rating）的股票平均推荐为 “持有”。一位股票研究分析师对该股进行了卖出评级，一位给出了持有建议，两位给出了买入建议。去年对该股发布评级的经纪商的12个月平均价格目标为40.00美元。
Several brokerages have issued reports on VERV. Cantor Fitzgerald began coverage on Verve Therapeutics in a research report on Wednesday. They issued a "neutral" rating and a $21.00 target price on the stock. Royal Bank of Canada dropped their target price on Verve Therapeutics from $42.00 to $35.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 8th. The Goldman Sachs Group began coverage on Verve Therapeutics in a research report on Thursday, December 15th. They issued a "sell" rating and a $13.00 target price on the stock. Finally, Credit Suisse Group dropped their target price on Verve Therapeutics to $37.00 in a research report on Tuesday, November 15th.
几家经纪公司已经发布了有关VERV的报告。坎托·菲茨杰拉德在周三的一份研究报告中开始报道Verve Therapeutics。他们对该股发布了 “中性” 评级和21.00美元的目标价格。加拿大皇家银行在11月8日星期二的一份研究报告中将Verve Therapeutics的目标价格从42.00美元下调至35.00美元，并对该股设定了 “跑赢大盘” 的评级。高盛集团在12月15日星期四的一份研究报告中开始报道Verve Therapeutics。他们对该股发布了 “卖出” 评级和13.00美元的目标价。最后，瑞士信贷集团在11月15日星期二的一份研究报告中将Verve Therapeutics的目标价格下调至37.00美元。
Verve Therapeutics Stock Down 3.0 %
Verve Therapeutics 股票下跌 3.
Shares of NASDAQ VERV opened at $23.29 on Wednesday. Verve Therapeutics has a twelve month low of $10.70 and a twelve month high of $43.00. The firm has a market cap of $1.43 billion, a P/E ratio of -8.03 and a beta of 1.54. The company has a 50 day moving average of $21.14 and a 200 day moving average of $28.48.
纳斯达克VERV的股价周三开盘价为23.29美元。Verve Therapeutics创下十二个月低点10.70美元，十二个月高点为43.00美元。该公司的市值为14.3亿美元，市盈率为-8.03，beta值为1.54。该公司的50天移动平均线为21.14美元，200天移动平均线为28.48美元。
Institutional Inflows and Outflows
机构流入和流出
A number of large investors have recently made changes to their positions in VERV. Swiss National Bank lifted its position in shares of Verve Therapeutics by 8.1% during the 1st quarter. Swiss National Bank now owns 39,900 shares of the company's stock valued at $911,000 after buying an additional 3,000 shares in the last quarter. ProShare Advisors LLC raised its stake in Verve Therapeutics by 15.6% during the 1st quarter. ProShare Advisors LLC now owns 11,817 shares of the company's stock valued at $270,000 after purchasing an additional 1,595 shares during the period. Bank of New York Mellon Corp raised its stake in Verve Therapeutics by 46.3% during the 1st quarter. Bank of New York Mellon Corp now owns 115,787 shares of the company's stock valued at $2,642,000 after purchasing an additional 36,652 shares during the period. MetLife Investment Management LLC raised its stake in Verve Therapeutics by 260.1% during the 1st quarter. MetLife Investment Management LLC now owns 20,938 shares of the company's stock valued at $478,000 after purchasing an additional 15,124 shares during the period. Finally, Rhumbline Advisers raised its stake in Verve Therapeutics by 107.5% during the 1st quarter. Rhumbline Advisers now owns 36,980 shares of the company's stock valued at $844,000 after purchasing an additional 19,156 shares during the period. 98.52% of the stock is owned by hedge funds and other institutional investors.
许多大型投资者最近更改了他们在VERV的头寸。瑞士国家银行在第一季度将其在Verve Therapeutics的股票头寸上调了8.1％。瑞士国家银行在上个季度又购买了3,000股股票后，现在拥有该公司39,900股股票，价值91.1万美元。ProShare Advisors LLC在第一季度将其在Verve Therapeutics的股份提高了15.6％。ProShare Advisors LLC在此期间又购买了1,595股股票后，现在拥有该公司11,817股股票，价值27万美元。纽约银行梅隆公司在第一季度将其在Verve Therapeutics的股份提高了46.3％。纽约银行梅隆公司在此期间又购买了36,652股股票后，现在拥有该公司115,787股股票，价值264.2万美元。大都会人寿投资管理有限责任公司在第一季度将其在Verve Therapeutics的股份提高了260.1％。大都会人寿投资管理有限责任公司在此期间又购买了15,124股股票后，现在拥有该公司20,938股股票，价值47.8万美元。最后，Rhumbline Advisers在第一季度将其在Verve Therapeutics的股份提高了107.5％。Rhumbline Advisers在此期间又购买了19,156股股票后，现在拥有该公司36,980股股票，价值84.4万美元。该股票的98.52％归对冲基金和其他机构投资者所有。
About Verve Therapeutics
关于 Verve Therapeu
(Get Rating)
（获取评分）
Verve Therapeutics, Inc, a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
Verve Therapeutics, Inc是一家遗传药物公司，致力于为患者开发治疗心血管疾病的基因编辑药物。其主要候选产品是 VERVE-101，这是一种单疗程基因编辑疗法，可永久关闭肝脏中的 PCSK9 基因。该公司还参与开发 ANGPTL3 计划，以永久关闭肝脏中的 ANGPTL3 基因。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Verve Therapeutics (VERV)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取 StockNews.com 关于 Verve Therapeutics (VERV) 的研究报告
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet的收益超过预期，增长可能会被定价
- 人工智能软件制造商 EPAM 拥有最大的科技板块涨势
- 在收益大幅下滑之后，福特股票将向前发展
- 内部人士和机构在全球范围内收购金刚狼
Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Verve Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Verve Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。